# Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

> **NCT00085462** · PHASE1 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 61 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** gp100-fowlpox vaccine
- **BIOLOGICAL:** therapeutic autologous lymphocytes
- **BIOLOGICAL:** therapeutic tumor infiltrating lymphocytes
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00085462
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2007-05
- **Final completion:** 2008-09
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2012-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085462, "Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00085462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*